Prostate-Specific Antigen (Semenogelase)

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

Also Known As:

Networked: 15321 relevant articles (448 outcomes, 1751 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lilja, Hans: 129 articles (01/2021 - 08/2002)
2.	Freedland, Stephen J: 128 articles (12/2021 - 02/2002)
3.	Scardino, Peter T: 107 articles (01/2022 - 03/2002)
4.	Partin, Alan W: 105 articles (01/2021 - 01/2002)
5.	D'Amico, Anthony V: 103 articles (10/2021 - 03/2002)
6.	Roobol, Monique J: 102 articles (01/2022 - 01/2002)
7.	Graefen, Markus: 98 articles (01/2022 - 03/2002)
8.	Thompson, Ian M: 92 articles (01/2022 - 06/2003)
9.	Epstein, Jonathan I: 89 articles (01/2021 - 01/2002)
10.	Carroll, Peter R: 86 articles (01/2022 - 07/2002)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 10/14/2023 - "Most prostate cancers(PCa) rely on serum prostate-specific antigen (PSA) testing for biopsy confirmation, but the accuracy needs to be further improved. " 05/01/2012 - "The introduction of serum prostate-specific antigen (PSA) in the 1980s has dramatically altered and benefited the initial diagnosis of prostate cancer. " 02/01/2008 - "The prostate-specific antigen value and the percent positive biopsy cores can be helpful in identifying men with high-grade prostate cancer most likely to benefit from RP. " 01/01/2004 - "The use of total prostate-specific antigen (tPSA) measurement has dramatically improved the ability to detect prostate cancer at earlier stages. " 01/01/2001 - "Prostate-specific antigen (PSA) has been extremely helpful in the detection of new or recurrent prostate cancer. "
2.	Neoplasms (Cancer) 02/01/2014 - "Furthermore, when compared with Duopafei®, the DTX-PMs dramatically reduced the prostate specific antigen (PSA) level and tumor growth of prostate tumor-bearing nude mice in vivo. " 06/01/2011 - "Most tumors respond favorably to these treatments, exhibiting regression of the tumor, amelioration of symptoms, and a decrease of prostate-specific antigen in patient sera. " 10/01/2018 - "Prostate specific antigen density improved the performance of prostate specific antigen to detect significant cancer (AUC 0.58 to 0.68) and any cancer (AUC 0.55 to 0.69, each p <0.001). " 01/01/2014 - "Results showed a significant reduction in tumor size, as evidenced by magnetic resonance imaging and color Doppler, as well as a an undetectable level of prostate specific antigen during, and immediately following treatment. " 06/01/2012 - "The prostate specific antigen (PSA) test, for instance, is subject to high levels of false positive results and cannot distinguish between cancer confined to the prostate and aggressive metastatic cancer. "
3.	Neoplasm Metastasis (Metastasis) 08/01/2006 - "As expected, patients with skeletal metastases had a significantly greater mean serum total prostate-specific antigen level, and a Gleason sum of 8 or 9 was significantly more frequent in the pathologic findings of these subjects. " 02/01/1999 - "The better efficacy of prostate specific antigen for the prediction of bone metastases was obtained with a cutoff value of 50 ng/ml (sensitivity 72%, specificity 86%). " 08/01/1995 - "Long-term followup data will be needed to determine whether there will be a lower incidence of biochemical relapse as determined by prostate specific antigen, local recurrence or metastasis, with an improvement in patient survival." 03/01/1992 - ""Prostate-specific" immunohistochemical techniques and serum prostate-specific antigen levels may be helpful in determining whether a particular metastases is from the prostate. " 10/01/2021 - "Using a quasi-randomized study design known as regression discontinuity (RD) and adjusting for lead-time bias, we compared metastasis-free survival (MFS) at 5 and 10 years after surgery between eSRT (prostate-specific antigen [PSA] <0.5 ng/ml) and lSRT (PSA ≥ 0.5 ng/ml). "
4.	Carcinoma (Carcinomatosis) 10/22/2019 - "Background: The aim of the present study is to analyze the efficacy of 68Gallium (Ga)-PSMA-11 PET/CT for detecting and localizing recurrent prostate carcinoma (PC) in patients with different prostate-specific antigen (PSA), PSA velocity (PSAvel) and doubling time (PSAdt). " 12/01/2001 - "The purpose of this study was to evaluate the efficacy of various diagnostic tests including transrectal ultrasound (TRUS), TRUS guided biopsy, digital rectal examination (DRE), prostate specific antigen (PSA), and prostate specific antigen density (PSAD) in detecting prostatic carcinomas. " 05/15/1995 - "This study was undertaken to assess the predictive value of pretreatment prostate-specific antigen (PSA) and the difference between clinical and PSA disease-free status in patients with long-term follow-up after irradiation for prostatic carcinoma. " 06/01/2019 - "Currently, prostate carcinoma's diagnosis is achieved by transrectal ultrasound-guided biopsy (gold-standard), usually requested after an elevation of prostate specific antigen (PSA) levels or an abnormal digital rectal exam or transrectal ultrasound. " 12/01/1995 - "The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the specificity of total serum PSA for the detection of prostate carcinoma in selected populations. "
5.	Pain (Aches) 11/01/2011 - "A significant decrease in pain and voiding signs/symptoms and a significant reduction in inflammatory leukocyte counts and serum prostate-specific antigen (PSA) were sustained throughout an 18-month follow-up period in both groups. " 09/01/2004 - "Therapeutic efficacy was assessed by serial evaluation of serum prostate-specific antigen (PSA) concentrations and by serial measurement of pain levels (using a VAS ranging from 0 to 10). " 11/01/1990 - "Three patients (20%) had a prolonged response (greater than or equal to 8 months) as seen by a persistently decreasing prostate specific antigen and improvement in bone pain. " 01/01/2017 - "Prostate-specific antigen level response was associated with stable physical functioning and improvement in pain. " 06/26/2014 - "A response end point was the primary end point in 9 studies, in 3 it was prostate-specific antigen (PSA)-related, in 3 pain-related and in 3 mixed. "

Related Drugs and Biologics

1.	Androgens
2.	Biomarkers (Surrogate Marker)
3.	Hormones (Hormone)
4.	Antigens
5.	Docetaxel (Taxotere)
6.	enzalutamide
7.	Alkaline Phosphatase
8.	Testosterone (Sustanon)
9.	Finasteride (Propecia)
10.	Acid Phosphatase

Related Therapies and Procedures

1.	Therapeutics
2.	Prostatectomy (Retropubic Prostatectomy)
3.	Radiotherapy
4.	Castration
5.	Drug Therapy (Chemotherapy)